TME Pharma NV
ALTME
Company Profile
Business description
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).
Contact
Max-Dohrn-Street 8-10
Berlin10589
DEUT: +49 30166370820
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,922.00 | 4.90 | 0.05% |
CAC 40 | 7,632.01 | 85.85 | 1.14% |
DAX 40 | 23,757.69 | 331.72 | 1.42% |
Dow JONES (US) | 44,144.62 | 556.04 | 1.28% |
FTSE 100 | 9,128.30 | 59.72 | 0.66% |
HKSE | 24,733.45 | 225.64 | 0.92% |
NASDAQ | 21,007.35 | 357.21 | 1.73% |
Nikkei 225 | 40,290.70 | 508.90 | -1.25% |
NZX 50 Index | 12,684.04 | 45.36 | -0.36% |
S&P 500 | 6,320.93 | 82.92 | 1.33% |
S&P/ASX 200 | 8,663.70 | 1.70 | 0.02% |
SSE Composite Index | 3,583.31 | 23.36 | 0.66% |